

JOHN A. LAHIVE, JR. (1928-1997) THOMAS V SMURZYNSKI RALPH A. LOREN GIULIO A. DeCONTI, JR. ELIZABETH A. HANLEY AMY BAKER MANDRAGOURAS ANTHONY A. LAURENTANO KEVIN J. CANNING JANE E. REMILLARD DeANN FORAN SMITH DEBRA J. MILASINCIC, Ph.D. WILLIAM A. SCOFIELD, JR. SIBLEY P. REPPERT DAVID J. RIKKERS DAVID R. BURNS JOHN S. CURRAN SEAN D. DETWEILER MEGAN E. WILLIAMS, Ph.D.

LISA DIROCCO TYNER
HATEAWAY P. RUSSELL *
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.
MERIDETH C. ARNOLD
DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROOS
PETER W. DINI, Ph.D.

SENIOR COUNSEL JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS
THEODORE R. WEST
JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL ANN MELLO, Ph.D.

TECHNICAL SPECIALISTS
CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
ANNE JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.

- Admitted in TX only
- ** Admitted in CT only

March 2, 2004

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FAX (617) 742-4214

lc@lahive.com

Re:

U.S. Patent Application No.: 10/731,463

For: Amidine Derivatives for Treating Amyloidosis

Inventors: Chalifour, Robert J., et al.

Filed: December 5, 2003 Our Ref. No.: NBI-105CN

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

- 1. Supplemental Information Disclosure Statement (2 pages);
- 2. PTO Form SB-08 (1 page);
- 3. A Copy of reference cited in said PTO Form SB-08 (1 reference);
- 4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Chalifour, Robert J., et al.

Serial No.: 10/731,463

Filed: December 5, 2003

For: AMIDINE DERIVATIVES FOR TREATING

AMYLOIDOSIS

Attorney Docket No.: NBI-105CN

Group Art Unit: 1621

Examiner: Not Yet Assigned

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in a package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

March 2, 2004

Date of Signature and of Mail Deposit

By:

Diegeore R. West

Registration No. 47,202

Agent for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their representatives are aware of the publication, listed on the attached PTO Form SB-08, and in accordance with 37 CFR §1.97 hereby submit this publication for the Examiner's consideration. A copy of the cited publication is enclosed.

The enclosed publication was disclosed to the PTO in the Information Disclosure Statement (IDS), and it was listed in the PTO Form 1449 that was filed yesterday (March 1, 2004). A copy of the publication however was inadvertently not enclosed in the package with the rest of the publications that were submitted with the aforementioned IDS.

This statement is not to be interpreted as a representation that the cited publication is material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of this publication be construed *per se* as a representation that such publication is prior art. Moreover, Applicants understand that the Examiner will make an independent evaluation of the cited publication.

No additional costs are believed to be due in connection with the filing of this Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080.

Respectfully submitted, LAHIVE & COCKFIELD, LLP

Theodore R. West Registration No. 47,202

Agent for Applicants

28 State Street Boston, MA 02109 (617) 227-7400

GAD/EAH/TRW/DLH/ipc

Enclosures

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substage for form 1449A/B/PTO

1

Sheet

MFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

(Ose as many sneets as necessary)

Complete if Known			
Application Number	10/731463		
Filing Date	December 5, 2003		
First Named Inventor	Chalifour, Robert J.		
Art Unit	1621		
Examiner Name	Not Yet Assigned		
Attorney Docket Number	NBI-105CN		

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

1

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (<i>if known</i>)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
	G1	WO 03/017994 A1	03-06-2003	Neurochem Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date
Signature	Considered

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.